References
- Berg K. A new serum type system in man—the LP system. Acta Pathol Microbiol Scand 1963; 59: 369–389
- Murai A., Miyahara T., Fujimoto K. N., Matsuda M., Kameyama M. Lp(a) lipoprotein as a risk factor for coronary heart disease and cerebral infarction. Atherosclerosis 1986; 59: 199–204
- Utermann G. The mysteries of lipoprotein(a). Science 1989; 246: 904–910
- Mbewu A., Durrington PN. Lipoprotein(a): Structure, properties and possible involvement in thrombogenesis and atherogenesis. Atherosclerosis 1990; 85: 1–47
- Lundin AP, III, Adler A. J., Feiroch AV. Maintenance hemodialy-sis: Survival beyond the first decade. J Am Med Assoc 1980; 244: 38–40
- Ritz E., Augustin J., Bommers J., Grasso A., Haberbosch W. Should hyperlipidemia of renal failure be treated. Kidney Int. 1985; 28((S17))584–587
- Ponticelli C., Barbe G., Cataluppi A., Donati C., Annoni G., Bran-cacci D. Lipid abnormalities in maintenance dialysis patients and renal transplant recipients. Kidney Int. 1978; 13: 572–578
- Papadopolus N. M., Borer W. Z., Elin R. J., Diamond LH. An abnormal lipoprotein in the serum of uremic patients maintained on chronic hemodialysis. Ann Int Med 1980; 92: 634–635
- Albers J. J., Cabana V. G., Warnick G. R., Hazzard WR. Lp(a) lipoprotein: Relationship to sinking pre-β lipoprotein, hyperli-poproteinemia and apolipoprotein B. Metabolism 1975; 24: 1047–1054
- Vessby B., Kostner G., Lthell H., Thomis J. Diverging effects of cholestyramine on apolipoprotein B and lipoprotein Lp(a). Atherosclerosis 1982; 44: 61–91
- Kostner G. M., Gavish D., Leopold B., Bolanzo K., Weintraub M. S., Breslow JL. HMC CoA reductase inhibitors lower LDL cholesterol without reducing Lp(a) levels. Circulation 1989; 80: 1313–1319
- Maeda S., Okuno M., Abe A., Noma A. Lack of effect of probucol on serum lipoprotein(a) levels. Atherosclerosis 1989; 79: 267–269
- Gurakar A., Hoeg J. M., Kostner G., Papadopoulus N. M., Brewer HB, jr. Levels of lipoprotein Lp(a) decline with neomycin and niacin treatment. Atherosclerosis 1985; 57: 293–301
- Carlson L. A., Hamster A., Asplund A. Pronounced lowering of serum levels of lipoprotein Lp(a) in hyperlipidaemic subjects treated with nicotinic acid. J Intern Med 1989; 226: 271–276
- Albers J. J., Taggart H. M., Applebaum-Bowden D., Haffner S., Chestnut, III, Hazzard WR. Reduction of lecithin-cholesterol acyltrasferase, apolipoprotein D and the Lp(a) lipoprotein with the anabolic steroid stanozol. Biochim Biophys Acta 1984; 795: 293–296
- Noma A., Maeda S., Okuno M., Abe A., Muto Y. Reduction of serum lipoprotein(a) levels in hyperlipidaemic patients with a-tocopheryl nicotinate. Atherosclerosis 1990; 84: 213–217
- Kostner GM. Recent Aspects of Diagnosis and Treatment of Lipoprotein Disorders. The affect of lipoprotein-a by lipid lowering drugs, K. Windholm, HK Naito, 1988; 255